These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15809479)

  • 21. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine.
    Blasberg RG; Roelcke U; Weinreich R; Beattie B; von Ammon K; Yonekawa Y; Landolt H; Guenther I; Crompton NE; Vontobel P; Missimer J; Maguire RP; Koziorowski J; Knust EJ; Finn RD; Leenders KL
    Cancer Res; 2000 Feb; 60(3):624-35. PubMed ID: 10676646
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of clinical usefulness of 131I alpha-methyl-tyrosine and fused SPECT/MRI imaging for diagnostics of recurrent cerebral gliomas.
    Górska-Chrzastek M; Grzelak P; Bieńkiewicz M; Tybor K; Zakrzewska E; Mikołajczak R; Stefańczyk L; Kuśmierek J
    Nucl Med Rev Cent East Eur; 2004; 7(2):135-41. PubMed ID: 15968600
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Kinetic analysis of 3'-deoxy-3'-18F-fluorothymidine in patients with gliomas.
    Muzi M; Spence AM; O'Sullivan F; Mankoff DA; Wells JM; Grierson JR; Link JM; Krohn KA
    J Nucl Med; 2006 Oct; 47(10):1612-21. PubMed ID: 17015896
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results.
    Reardon DA; Quinn JA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Dowell JM; Rich JN; Vredenburgh JJ; Desjardins A; Sampson JH; Gururangan S; Wong TZ; Badruddoja MA; Zhao XG; Bigner DD; Zalutsky MR
    J Nucl Med; 2006 Jun; 47(6):912-8. PubMed ID: 16741299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model.
    van Waarde A; Cobben DC; Suurmeijer AJ; Maas B; Vaalburg W; de Vries EF; Jager PL; Hoekstra HJ; Elsinga PH
    J Nucl Med; 2004 Apr; 45(4):695-700. PubMed ID: 15073267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
    Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA
    J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pegylated Arg-Gly-Asp peptide: 64Cu labeling and PET imaging of brain tumor alphavbeta3-integrin expression.
    Chen X; Hou Y; Tohme M; Park R; Khankaldyyan V; Gonzales-Gomez I; Bading JR; Laug WE; Conti PS
    J Nucl Med; 2004 Oct; 45(10):1776-83. PubMed ID: 15471848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
    Cher LM; Murone C; Lawrentschuk N; Ramdave S; Papenfuss A; Hannah A; O'Keefe GJ; Sachinidis JI; Berlangieri SU; Fabinyi G; Scott AM
    J Nucl Med; 2006 Mar; 47(3):410-8. PubMed ID: 16513609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatial heterogeneity of low-grade gliomas at the capillary level: a PET study on tumor blood flow and amino acid uptake.
    Wyss MT; Hofer S; Hefti M; Bärtschi E; Uhlmann C; Treyer V; Roelcke U
    J Nucl Med; 2007 Jul; 48(7):1047-52. PubMed ID: 17574979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of O-(2-18F-fluoroethyl)-L-tyrosine PET and 3-123I-iodo-alpha-methyl-L-tyrosine SPECT in brain tumors.
    Pauleit D; Floeth F; Tellmann L; Hamacher K; Hautzel H; Müller HW; Coenen HH; Langen KJ
    J Nucl Med; 2004 Mar; 45(3):374-81. PubMed ID: 15001676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison between contrast-enhanced magnetic resonance imaging and technetium 99m glucohepatonic acid single photon emission computed tomography with histopathologic correlation in gliomas.
    Kumar RA; Khandelwal N; Sodhi KS; Pathak A; Mittal BR; Radotra BD; Suri S
    J Comput Assist Tomogr; 2006; 30(5):723-33. PubMed ID: 16954918
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance.
    Diaz RJ; Dios RR; Hattab EM; Burrell K; Rakopoulos P; Sabha N; Hawkins C; Zadeh G; Rutka JT; Cohen-Gadol AA
    J Neurosurg; 2015 Jun; 122(6):1360-9. PubMed ID: 25839919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
    Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
    J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction of hyperintense signal on T2-weighted MR images correlates with infusion distribution from intracerebral convection-enhanced delivery of a tumor-targeted cytotoxin.
    Sampson JH; Raghavan R; Provenzale JM; Croteau D; Reardon DA; Coleman RE; Rodríguez Ponce I; Pastan I; Puri RK; Pedain C
    AJR Am J Roentgenol; 2007 Mar; 188(3):703-9. PubMed ID: 17312057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Convection-enhanced delivery of boronated epidermal growth factor for molecular targeting of EGF receptor-positive gliomas.
    Yang W; Barth RF; Adams DM; Ciesielski MJ; Fenstermaker RA; Shukla S; Tjarks W; Caligiuri MA
    Cancer Res; 2002 Nov; 62(22):6552-8. PubMed ID: 12438250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.
    Schumacher T; Hofer S; Eichhorn K; Wasner M; Zimmerer S; Freitag P; Probst A; Gratzl O; Reubi JC; Maecke R; Mueller-Brand J; Merlo A
    Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):486-93. PubMed ID: 11914886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDOPA kinetics in brain tumors.
    Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
    J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Yordanov AT; Hens M; Pegram C; Bigner DD; Zalutsky MR
    Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.